Additionally, UCMSCs-primed Tregs of MS patients significantly inhibited the proliferation of PHA-stimulated autologous and allogenic CD4+CD25— T effector cells (Teffs) from MS patients and healthy individuals, compared to non-UCMSCs-primed Tregs from the same MS patients (P < 0.01). The gene discussed is CD4; the disease is myeloid sarcoma.